Northrop Grumman (NOC)
NYSEIndustrialsAerospace & DefenseSnapshot 2026-10-30
$557.54-0.86%
Close 2026-10-30 · 1-day change
NYSEIndustrialsAerospace & DefenseSnapshot 2026-10-30
Research Workspace
Put NOC beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Aerospace & Defense is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — EPS near $27.65 in FY26: Diluted EPS: $7.89 per share.
View ThesisRevenue is growing steadily — about 7% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskNorthrop Grumman’s case rests on expanding production capacity and accelerating key programs, with revenue growth strengthening. Revenue growth rose from 4% to 7% year over year, and Q3 EPS beat consensus. Northrop trades at 19× earnings versus a 29× peer median. The price reflects less growth than our forecast, despite that valuation gap. Fragile cash backing and EPS near $27.65 in FY26 face pressure against reported diluted EPS of $7.89. Our model puts the next-quarter miss probability near 16%. Peer multiples imply a price roughly in line with where it trades (about fair); the thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-30. NOC is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 28 analysts currently covering NOC (as of Oct 2026).
Based on 13 Wall Street analysts offering 12-month price targets for NOC in the last 4 months.
Continue this research
Compare NOC with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| NOC Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Aerospace & Defense — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put NOC next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Grow sales while reaffirming and raising financial guidance
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $557.54
The last 12 months of price, then the range of analyst 12-month targets from today’s $557.54.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Reported results cite substantial backlog and improving margins, supporting growth and operating performance.
Advances: Grow sales while reaffirming and raising financial guidance
2027 growth outlook and maintained cash-flow target support growth and cash objectives.
Advances: Grow sales while reaffirming and raising financial guidance
Earnings-call disclosures provide current evidence on performance and guidance.
Advances: Reaffirm and raise 2026 financial guidance for sales and EPS
Reported 2026 profit outlook increases support earnings growth, though the headline provides no guidance details.
Advances: Grow sales while reaffirming and raising financial guidance
Estimate beat and $110 billion backlog support growth and program demand.
Advances: Reaffirm and raise 2026 financial guidance for sales and EPS
Raised sales and earnings outlook directly advances the 2026 guidance objective.
Advances: Reaffirm and raise 2026 financial guidance for sales and EPS
Profit beat and higher 2026 earnings outlook confirm improving guidance.
Advances: Reaffirm and raise 2026 financial guidance for sales and EPS
Higher profit forecast and record backlog strengthen 2026 outlook.
